Replies to post #373182 on Innovation Pharmaceuticals Inc (IPIX)

[DonnyBaseball516]

The biggest indicator of future behavior is past behavior.

[kfcyahoo]

"IPIX would not be in this enviable pandemic-position had it not been for the alert and quick actions of L......"

Yeah. Appears he really blew his mind orchestrating that purchase and has yet to catch his wind back.

[steelyeye]

Post should be stickied. You provide good context and history for Brilacidin, as well as where we stand today.

Brilacidin is on the "radar" of the U.S. Gov't just as the Biden administration announces plans to spend $36B on the development of new vaccines and therapeutics.

Data lock coming any day now.

[monentum2play]

He will have to partner or license it out for royalty
He doesn't have a manufacturing facility. He need to dispense in pill form or mist toget it out there fast

[loanranger]

"Thanks Leo: Brilacidin Acquired On 9/4/2013"
Do you think the Accountant or the Dr. was the driving force behind that acquisition?

10/14/13 release:
“More than two million Americans acquire serious bacterial infections annually. The CDC has made it clear as to how critical it is to develop new therapies to address this fact, which has recently been highlighted by news of National Football League and NFL Players Association acknowledging a problem with MRSA infections.” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Brilacidin is the first of an entirely new class of antibiotics, known as defensin-mimetics. It can rapidly kill the bacteria that cause ABBBSI, including resistant strains of Staph aureus, such as MRSA. Also, unlike most antibiotics, Brilacidin has minimal potential to promote the further development of resistant strains. This is because of its unique mechanism of action, as well as its ability to be given as a short course regimen, perhaps as a single dose. Both single and 3-day dosing regimens will be explored in the upcoming phase 2b study. Single-dose therapy removes patient non-adherence as a driver of antimicrobial resistance, and it allows for reduced health care costs, as patients do not need to return to the clinic or hospital for additional doses.”

"Brilacidin could be the key antibiotic on the horizon for serious skin infections. Based on sales of antibiotic compounds and recent billion-dollar acquisitions that reflect the value of new antibiotics, we are very excited and believe that an FDA approved Brilacidin would capture a significant share of the ABSSSI market, due to its unique attributes, including short-course therapy,” commented Krishna Menon, chief scientific officer at Cellceutix.

Dr Menon continued: “With ABSSSI as the lead indication, followed by other possible uses for infected wounds, bone, joint and blood stream infections, Brilacidin could fill a large void in the dwindling global portfolio of effective antibiotics. Our strategy includes capitalizing on the Generating Antibiotics Incentives Now (GAIN) Act, which, combined with other government efforts, is positively changing the regulatory climate in the developmental of drugs like Brilacidin."

http://www.ipharminc.com/press-release/2016/11/16/cellceutix-drug-brilacidin-may-be-the-key-antibiotic-on-the-horizon-for-serious-skin-infections-plans-to-start-phase-2b-study-in-january-2014

[MackG]

Nice recap. Thanks.

[CallMeCrazy]

'60 Minutes' Segment (13:26) Stopping Pandemics Forever

If successful, and DARPA has a track record with many successes, this could make viral vaccines and therapeutics obsolete.

Hopefully, IPIX will have made its billion$ before any of this happens, if it happens.

https://www.cbsnews.com/video/last-pandemic-science-military-60-minutes-video-2021-09-05/#x

P.S. Looks great on full screen.